FLT3 and acute myeloid leukemia: Importantly, significant CEBPA upregulation (3-fold; p < 0.001) was observed upon treating a patient sample (named AML3: a 62-year-old male with IDH2, DNMT3A, NMP1, and FLT3-ITD mutated AML) ex vivo with MTL-CEBPA (Figure 3C), supporting that RNA activation via MTL-CEBPA extends beyond immortalized cell lines.